Thanks To UK Funding, Cambridge University Joins Race To Find a Cure

Cambridge University
Ongoing pandemic spurred the race of new approaches to vaccine-making

Firstly, the University Of Cambridge is also aiming to start clinical trials. As a result of receiving 1.9 million pounds in funding from the British Government. The infection, which causes the disease COVID-19, has spread to each edge of the globe.
The scientist however said that they would be using the genetic sequence of all coronaviruses. This could certainly help in bringing forward an immune response. Moreover, it could help in avoiding the adverse effects of a hyper-inflammatory immune response.
Jonathan Heeney head of the laboratory of Viral Zoonotic said –

“We’re looking for chinks in its armor.”
“Crucial pieces of the virus that we can use to construct the vaccine.”

“Furthermore we aim to make a vaccine that will not only protect from SARS-COV-2”
“But also other related coronaviruses that may spill over from animal to humans”

As of now, there is no effective vaccine against COVID-19. The Cambridge DIOS-CoVax2 is a DNA based. It is a computer-generated antigen structure encoded using a synthesis gene. This vaccine would have the ability to re-program the body’s immune system. Moreover, it will help the body to produce antibodies against the coronaviruses.

The method used aka DNA vector method shows promising results. It is effective at stimulating an immune response in other pathogens. – says the University. Altogether, DOIS-CoVax2 does not need a cold temperature. It offers flexibility in using needles. Hence making a widespread distribution of vaccines very simple and easier.

Thanks to scientists from the University on winning funding from the U.K. government. Today 30+ COVID vaccines are in clinical trials. Around 140 are at a per-clinical stage, says the World Health Organization. Other forerunner includes the University Of Oxford.

Ongoing pandemic spurred the race of new approaches to vaccine-making. DNA-based vaccines are showing positive immune responses. On the other hand, some investors are complaining about the lack of details.